D.4 Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results. - Mendell, JR; Muntoni, F; McDonald, CM; Mercuri, EM; Ciafaloni, E; Komaki, H; Leon-Astudillo, C; Nascimento, A; Proud, C; Schara-Schmidt, U; Veerapandiyan, A; Zaidman, CM; et al. (The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2024)